



Update - February, 2021



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

© P.J. Lansberg

Statin publications February 2021

Add on treatments

1. ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin-angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry. *Cardiology journal* 2021; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634844>
2. LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. *Cardiovasc Drugs Ther* 2021; Climent E, Bea AM, Benaiges D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33555511>
3. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A

- Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. Drug design, development and therapy 2021; 15:651-658; Yang E, Yoo H, Jang IJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628012>
4. Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training. Drugs Aging 2021; Alturki M, Liberman K, Delaere A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33543410>
 5. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. Eur J Prev Cardiol 2020; Blaum C, Seiffert M, Goßling A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580772>
 6. Physician variation in the de-adoption of ineffective statin and fibrate therapy. Health services research 2021; Everhart A, Desai NR, Dowd B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569804>
 7. Coenzyme Q(10) for Patients With Cardiovascular Disease: JACC Focus Seminar. J Am Coll Cardiol 2021; 77:609-619; Raizner AE, Quiñones MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33538259>
 8. Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat. Journal of diabetes and metabolic disorders 2020; 19:1415-1422; Mondol D, Islam MN, Biswas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553033>
 9. Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial. Journal of neurology 2021; Yang WY, Li YF, Wang ZR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33555418>
 10. Can Combination of Simvastatin and Melatonin Create a Synergistic Effect on Bone Regeneration? Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2021; Koç O, Tüz HH, Ocak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33524327>
 11. Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials. PLoS One 2021; 16:e0246480; Blais JE, Tong GKY, Pathadka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33561179>
 12. Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture. PLoS One 2021; 16:e0247153; Terceño M, Remollo S, Silva Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600491>
 13. [Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management]. Revue medicale de Liege 2021; 76:128-133; Lancellotti P, Ancion A, Scheen AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33543860>

14. Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4. *Toxicology letters* 2021; 342:85-94; Zheng N, Wei A, Wu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600922>

Adherence

1. Cardiovascular event rates increase after each recurrence and associate with poor statin adherence. *Eur J Prev Cardiol* 2020; Lassenius MI, Toppila I, Bergius S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611439>
2. Statin nonadherence in Latino and noncitizen neighborhoods in New York City, Los Angeles, and Chicago, 2012-2016. *Journal of the American Pharmacists Association : JAPhA* 2021; Guadamuz JS, Durazo-Arvizu RA, Daviglius ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33637436>
3. Achieving optimal adherence to medical therapy by telehealth: Findings from the ORBITA medication adherence sub-study. *Pharmacol Res Perspect* 2021; 9:e00710; Thompson D, Al-Lamee R, Foley M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33570248>
4. Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. *Research in social & administrative pharmacy : RSAP* 2021; Seaman KL, Bulsara MK, Sanfilippo FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33558155>

Atherosclerosis & Imaging

1. Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. *Angiogenesis* 2021; Baganha F, de Jong RCM, Peters EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33550461>
2. Impact of statin pretreatment on the complications of carotid stenting in asymptomatic patients: observational study. *BMC Neurol* 2021; 21:75; Jang SH, Kwon DH, Han MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33588788>
3. Reduced 18F-sodium fluoride activity in coronary plaques after statin therapy. *European heart journal cardiovascular Imaging* 2021; Dietz M, Chironi G, Faraggi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33537762>
4. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. *European heart*

- journal cardiovascular Imaging 2021; Ota H, Omori H, Kawasaki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33637979>
5. Aortic valvular stenosis - novel therapeutic strategies. European journal of clinical investigation 2021:e13527; Natorska J, Kopytek M, Undas A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33621361>
 6. Cardiovascular Risk in the Lung Cancer Screening Population: A Multicenter Study Evaluating the Association Between Coronary Artery Calcification and Preventive Statin Prescription. J Am Coll Radiol 2021; Tailor TD, Chiles C, Yeboah J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33640340>
 7. Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation? Kaohsiung J Med Sci 2021; Zhelyazkova-Savova MD, Yotov YT, Nikolova MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634559>
 8. Contribution of Risk Factors to the Development of Coronary Atherosclerosis as Confirmed via Coronary CT Angiography: A Longitudinal Radiomics-based Study. Radiology 2021:203179; Kolossváry M, Gerstenblith G, Bluemke DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591887>
 9. Effects of different statins application methods on plaques in patients with coronary atherosclerosis. World journal of clinical cases 2021; 9:812-821; Wu X, Liu XB, Liu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33585627>

Atorvastatin/Rosuvastatin

1. Rosuvastatin Attenuates Rheumatoid Arthritis-Associated Manifestations via Modulation of the Pro- and Anti-inflammatory Cytokine Network: A Combination of In Vitro and In Vivo Studies. ACS omega 2021; 6:2074-2084; Qasim S, Alamgeer, Kalsoom S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33521447>
2. Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. Angiogenesis 2021; Baganha F, de Jong RCM, Peters EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33550461>
3. Late response to rosuvastatin and statin-related myalgia due to SLC01B1, SLC01B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report. Annals of translational medicine 2021; 9:76; Dagli-Hernandez C, de Freitas RCC, Marçal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553369>
4. UPLC-MS/MS method for the simultaneous quantification of pravastatin, fexofenadine, rosuvastatin and methotrexate in a hepatic uptake model and its application to the possible drug-drug-interaction study of triptolide. Biomedical chromatography : BMC 2021:e5093; Wu W, Cheng R, Jiang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634891>

5. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. *BMC pharmacology & toxicology* 2021; 22:11; Choi JY, Choi CU, Choi BG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33541430>
6. LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. *Cardiovasc Drugs Ther* 2021; Climent E, Bea AM, Benaiges D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33555511>
7. Rosuvastatin Reduces L-Type Ca(2+) Current and Alters Contractile Function in Cardiac Myocytes via Modulation of β -Adrenergic Receptor Signaling. *Cardiovasc Toxicol* 2021; Ozturk N, Uslu S, Mercan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33565033>
8. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. *Clinical drug investigation* 2021; Caro L, Prueksaritanont T, Fandozzi CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33527237>
9. The effect of atorvastatin on recurrence of chronic subdural hematoma after novel YL-1 puncture needle surgery. *Clin Neurol Neurosurg* 2021; 202:106548; Wang D, Wang H, Xu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33609954>
10. Atorvastatin-Induced Refractory Thrombocytopenia. *Cureus* 2021; 13:e12502; Ghuman J, Manasewitsch NT, Ghuman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33564510>
11. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. *Drug design, development and therapy* 2021; 15:651-658; Yang E, Yoo H, Jang IJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628012>
12. Inhibition of the mevalonate pathway improves myocardial fibrosis. *Experimental and therapeutic medicine* 2021; 21:224; Xu H, Shen Y, Liang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33603833>
13. The ameliorative effect of atorvastatin on serum testosterone and testicular oxidant/antioxidant system of HFD-fed male albino rats. *F1000Research* 2020; 9:1300; Esmail M, Kandeil M, El-Zanaty AM, Abdel-Gabbar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628436>
14. Atorvastatin Attenuates Isoflurane-Induced Activation of ROS-p38MAPK/ATF2 Pathway, Neuronal Degeneration, and Cognitive Impairment of the Aged Mice. *Frontiers in aging neuroscience* 2020; 12:620946; Liu P, Gao Q, Guan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33519423>

15. Case Report: Hypertriglyceridemia and Premature Atherosclerosis in a Patient With Apolipoprotein E Gene $\epsilon 2\epsilon 1$ Genotype. *Frontiers in cardiovascular medicine* 2020; 7:585779; Limonova AS, Ershova AI, Meshkov AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33537346>
16. Analytical Quality by Design Approach of Reverse-Phase High-Performance Liquid Chromatography of Atorvastatin: Method Development, Optimization, Validation, and the Stability-Indicated Method. *International journal of analytical chemistry* 2021; 2021:8833900; Alruwaili NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628253>
17. Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation. *International journal of nanomedicine* 2021; 16:905-924; Verma R, Kaushik A, Almeer R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33603359>
18. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves' disease. *J Clin Endocrinol Metab* 2021; Nilsson A, Tsoumani K, Planck T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33560351>
19. Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat. *Journal of diabetes and metabolic disorders* 2020; 19:1415-1422; Mondol D, Islam MN, Biswas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553033>
20. Long-term Prognosis of Mild to Moderate Aortic Stenosis and Coronary Artery Disease. *J Korean Med Sci* 2021; 36:e47Lee W, Choi W, Kang SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33559407>
21. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. *Journal of translational medicine* 2021; 19:62; Zhang X, Qin Y, Wan X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33568202>
22. Effects of atorvastatin and resveratrol against the experimental endometriosis; evidence for glucose and monocarboxylate transporters, neoangiogenesis. *Life sciences* 2021; 272:119230; Bahrami A, Ayen E, Razi M, Behfar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600864>
23. Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out. *Lipids* 2021; Aksoy HN, Ceylan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611813>
24. Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases. *Molecular and cellular biochemistry* 2021; Beales ILP, Ogunwobi OO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33582946>

25. Comprehensive Study of Atorvastatin Nanostructured Lipid Carriers through Multivariate Conceptualization and Optimization. *Pharmaceutics* 2021; 13:Ghanem HA, Nasr AM, Hassan TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33525642>
26. Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study. *PLoS One* 2021; 16:e0247419; Kim J, Kim HS, Bae YJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630898>
27. [Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management]. *Revue medicale de Liege* 2021; 76:128-133; Lancellotti P, Ancion A, Scheen AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33543860>
28. Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. *Scientific reports* 2021; 11:4126; Hoogeveen RM, Verweij SL, Kaiser Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602971>
29. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. *Translational lung cancer research* 2021; 10:128-142; Luo Y, Yang Y, Peng P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569299>

Basic science

1. Rosuvastatin Attenuates Rheumatoid Arthritis-Associated Manifestations via Modulation of the Pro- and Anti-inflammatory Cytokine Network: A Combination of In Vitro and In Vivo Studies. *ACS omega* 2021; 6:2074-2084; Qasim S, Alamgeer, Kalsoom S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33521447>
2. Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization. *Angiogenesis* 2021; Baganha F, de Jong RCM, Peters EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33550461>
3. Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report. *Annals of translational medicine* 2021; 9:76; Dagli-Hernandez C, de Freitas RCC, Marçal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553369>
4. Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. *Anticancer Drugs* 2021; Asari K, Sun WT, Kok ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33587350>

5. Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines. *Asian Pacific journal of cancer prevention : APJCP* 2021; 22:33-42; Rezano A, Ridhayanti F, Rangkuti AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33576210>
6. UPLC-MS/MS method for the simultaneous quantification of pravastatin, fexofenadine, rosuvastatin and methotrexate in a hepatic uptake model and its application to the possible drug-drug-interaction study of triptolide. *Biomedical chromatography : BMC* 2021:e5093; Wu W, Cheng R, Jiang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634891>
7. SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets. *BMC Genomics* 2021; 22:125; Li Y, Duche A, Sayer MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602138>
8. Simvastatin attenuates spatial memory impairment via inhibiting microglial cell death against ethanol induced neurotoxicity in the developing rat hippocampus. *Brain Res* 2021:147341; Jafari M, Hojati V, Khaksari M, Vaezi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33548270>
9. Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. *Can Assoc Radiol J* 2021:846537120988262; Avery A, Sussman M, Longo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563030>
10. Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching. *Cancer research* 2021; Yu R, Longo J, van Leeuwen JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602786>
11. Rosuvastatin Reduces L-Type Ca(2+) Current and Alters Contractile Function in Cardiac Myocytes via Modulation of β -Adrenergic Receptor Signaling. *Cardiovasc Toxicol* 2021; Ozturk N, Uslu S, Mercan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33565033>
12. Targeting cholesterol metabolism as efficient antiviral strategy against the Hepatitis E virus. *Cell Mol Gastroenterol Hepatol* 2021; Glitscher M, Martín DH, Woytinek K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33601063>
13. Preparation, Characterization and in vitro/in vivo Evaluation of Lovastatin-Loaded PLGA Microspheres by Local Administration for Femoral Head Necrosis. *Drug design, development and therapy* 2021; 15:601-610; Sun Y, Long D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33623369>
14. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. *Eur J Prev Cardiol* 2020; Baragetti A, Bonacina F, Da Dalt L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624064>

15. Inhibition of the mevalonate pathway improves myocardial fibrosis. *Experimental and therapeutic medicine* 2021; 21:224; Xu H, Shen Y, Liang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33603833>
16. The ameliorative effect of atorvastatin on serum testosterone and testicular oxidant/antioxidant system of HFD-fed male albino rats. *F1000Research* 2020; 9:1300; Esmail M, Kandeil M, El-Zanaty AM, Abdel-Gabbar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628436>
17. Atorvastatin Attenuates Isoflurane-Induced Activation of ROS-p38MAPK/ATF2 Pathway, Neuronal Degeneration, and Cognitive Impairment of the Aged Mice. *Frontiers in aging neuroscience* 2020; 12:620946; Liu P, Gao Q, Guan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33519423>
18. Use of Simvastatin, Fibrin Clots, and Their Combination to Improve Human Ovarian Tissue Grafting for Fertility Restoration After Anti-Cancer Therapy. *Frontiers in oncology* 2020; 10:598026; Magen R, Shufaro Y, Daykan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33552971>
19. Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates. *Frontiers in pharmacology* 2020; 11:642171; Badr-Eldin SM, Alhakamy NA, Fahmy UA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33633571>
20. Analytical Quality by Design Approach of Reverse-Phase High-Performance Liquid Chromatography of Atorvastatin: Method Development, Optimization, Validation, and the Stability-Indicated Method. *International journal of analytical chemistry* 2021; 2021:8833900; Alruwaili NK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628253>
21. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. *Int J Cardiol* 2021; Jojima T, Sakurai S, Wakamatsu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556413>
22. Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation. *International journal of nanomedicine* 2021; 16:905-924; Verma R, Kaushik A, Almeer R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33603359>
23. Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat. *Journal of diabetes and metabolic disorders* 2020; 19:1415-1422; Mondol D, Islam MN, Biswas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553033>
24. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. *Journal of the National Cancer*

- Institute 2021; Bhat K, Saki M, Cheng F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556960>
25. The effect of topical administration of simvastatin on entochondrostosis and intramembranous ossification: An animal experiment. *J Orthop Translat* 2021; 28:1-9; Dang L, Zhu J, Song C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33575165>
26. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. *Journal of translational medicine* 2021; 19:62; Zhang X, Qin Y, Wan X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33568202>
27. Angiogenic Effect of Pravastatin Alone and with Sera from Healthy and Complicated Pregnancies Studied by in vitro Vasculogenesis/Angiogenesis Assay. *Journal of vascular research* 2021:1-9; Virtanen A, Huttala O, Tihtonen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33571991>
28. Interdependence of Anti-Inflammatory and Antioxidant Properties of Squalene-Implication for Cardiovascular Health. *Life (Basel)* 2021; 11; Ibrahim N, Naina Mohamed I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33573041>
29. Effects of atorvastatin and resveratrol against the experimental endometriosis; evidence for glucose and monocarboxylate transporters, neoangiogenesis. *Life sciences* 2021; 272:119230; Bahrami A, Ayen E, Razi M, Behfar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600864>
30. Comparison of the Effects of Statins on A549 Non-small-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out. *Lipids* 2021; Aksoy HN, Ceylan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611813>
31. Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves' Ophthalmopathy through the Regulation of FoxO3a Signaling. *Mediators Inflamm* 2021; 2021:8888913; Wei YH, Liao SL, Wang CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33542676>
32. Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice. *Mol Brain* 2021; 14:41; Guo Y, Zou G, Qi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33627175>
33. Structural basis for the biosynthesis of lovastatin. *Nature communications* 2021; 12:867; Wang J, Liang J, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33558520>
34. Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats. *Naunyn-Schmiedeberg's archives of pharmacology* 2021; Alshogran OY, Nusair SD, El-Elimat T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630121>

35. Comprehensive Study of Atorvastatin Nanostructured Lipid Carriers through Multivariate Conceptualization and Optimization. *Pharmaceutics* 2021; 13; Ghanem HA, Nasr AM, Hassan TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33525642>
36. Simvastatin suppresses renal cell carcinoma cells by regulating DDX5/DUSP5. *Scandinavian journal of urology* 2021:1-7; Qiu Y, Zhao Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517812>
37. Statin use is associated with reduced motor recovery after spinal cord injury. *Spinal Cord Ser Cases* 2021; 7:8; Triplet EM, Scarisbrick IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33536407>
38. Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4. *Toxicology letters* 2021; 342:85-94; Zheng N, Wei A, Wu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600922>
39. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. *Translational lung cancer research* 2021; 10:128-142; Luo Y, Yang Y, Peng P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569299>

Cancer

1. Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. *Anticancer Drugs* 2021; Asari K, Sun WT, Kok ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33587350>
2. Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines. *Asian Pacific journal of cancer prevention : APJCP* 2021; 22:33-42; Rezano A, Ridhayanti F, Rangkuti AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33576210>
3. Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. *Can Assoc Radiol J* 2021:846537120988262; Avery A, Sussman M, Longo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563030>
4. Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching. *Cancer research* 2021; Yu R, Longo J, van Leeuwen JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602786>
5. Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates. *Frontiers in pharmacology* 2020;

- 11:642171; Badr-Eldin SM, Alhakamy NA, Fahmy UA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33633571>
6. Cardiovascular Risk in the Lung Cancer Screening Population: A Multicenter Study Evaluating the Association Between Coronary Artery Calcification and Preventive Statin Prescription. *J Am Coll Radiol* 2021; Tailor TD, Chiles C, Yeboah J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33640340>
 7. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. *Journal of clinical gastroenterology* 2021; Hajifathalian K, Tafesh Z, Rosenblatt R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33606428>
 8. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. *Journal of clinical gastroenterology* 2021; Wong YJ, Qiu TY, Ng GK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33606427>
 9. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. *Journal of the National Cancer Institute* 2021; Bhat K, Saki M, Cheng F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556960>
 10. Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out. *Lipids* 2021; Aksoy HN, Ceylan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611813>
 11. Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases. *Molecular and cellular biochemistry* 2021; Beales ILP, Ogunwobi OO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33582946>
 12. Simvastatin suppresses renal cell carcinoma cells by regulating DDX5/DUSP5. *Scandinavian journal of urology* 2021:1-7; Qiu Y, Zhao Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517812>
 13. Venous thromboembolism and risk of cancer in users of statins: A Danish population-based cohort study. *Thrombosis research* 2021; 201:1-5; Skajaa N, Nagy D, Schønfeldt Troelsen F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33621859>
 14. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. *Translational lung cancer research* 2021; 10:128-142; Luo Y, Yang Y, Peng P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569299>
 15. [A Meta-analysis on association between statins and colorectal cancer]. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi* 2021; 42:343-350; Qi JH, Wei JN, Zhang ZJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33626626>

Children

1. Comparative study of the efficacy of captopril, simvastatin, and L-carnitine as cardioprotective drugs in children with type 1 diabetes mellitus: a randomised controlled trial. *Cardiology in the young* 2021;1-8; Badreldeen A, El Razaky O, Erfan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33536102>
2. 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease. *Current infectious disease reports* 2021; 23:3; Zhu F, Ang JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33584148>

Cost-effectiveness

1. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? *Diabetes Care* 2020; 43:1557-1592; Siegel KR, Ali MK, Zhou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33534729>
2. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. *Eur J Prev Cardiol* 2020; Blaum C, Seiffert M, Goßling A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580772>
3. Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. *Research in social & administrative pharmacy : RSAP* 2021; Seaman KL, Bulsara MK, Sanfilippo FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33558155>
4. Commentary: Atrial Fibrillation, Statin and Septal Myectomy. *Seminars in thoracic and cardiovascular surgery* 2021; Nguyen SN, Shimada YJ, Weiner SD, Takayama H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600974>

CVD

1. Comparison of Patients With Nonobstructive Coronary Artery Disease With Versus Without Myocardial Infarction (From the VA Clinical Assessment Reporting and Tracking [CART] Program). *Am J Cardiol* 2021; Kovach CP, Hebbe A, O'Donnell CI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33539858>
2. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. *Atherosclerosis. Supplements* 2020; 42:e59-e64; Alings M, Descamps O, Guillon B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589225>

3. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. *Atherosclerosis. Supplements* 2020; 42:e49-58; Landmesser U, Pirillo A, Farnier M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589224>
4. Consistent use of lipid lowering therapy in HIV infection is associated with low mortality. *BMC infectious diseases* 2021; 21:150; Drechsler H, Ayers C, Cutrell J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546621>
5. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. *BMC pharmacology & toxicology* 2021; 22:11; Choi JY, Choi CU, Choi BG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33541430>
6. ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin-angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry. *Cardiology journal* 2021; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634844>
7. 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease. *Current infectious disease reports* 2021; 23:3; Zhu F, Ang JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33584148>
8. Case report of a COVID-19-associated myocardial infarction with no obstructive coronary arteries: the mystery of the phantom embolus or local endothelitis. *European heart journal. Case reports* 2021; 5:ytaa521; Burkert FR, Niederreiter L, Dichtl W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598613>
9. Cardiovascular event rates increase after each recurrence and associate with poor statin adherence. *Eur J Prev Cardiol* 2020; Lassenius MI, Toppila I, Bergius S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611439>
10. Inhibition of the mevalonate pathway improves myocardial fibrosis. *Experimental and therapeutic medicine* 2021; 21:224; Xu H, Shen Y, Liang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33603833>
11. Case Report: Hypertriglyceridemia and Premature Atherosclerosis in a Patient With Apolipoprotein E Gene $\epsilon 2\epsilon 1$ Genotype. *Frontiers in cardiovascular medicine* 2020; 7:585779Limonova AS, Ershova AI, Meshkov AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33537346>
12. Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US. *Frontiers in medicine* 2021; 8:639804Marić I, Oskotsky T, Kostić I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33614688>
13. Cardiovascular Risk in the Lung Cancer Screening Population: A Multicenter Study Evaluating the Association Between Coronary Artery Calcification and

- Preventive Statin Prescription. *J Am Coll Radiol* 2021; Taylor TD, Chiles C, Yeboah J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33640340>
14. Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018. *J Am Geriatr Soc* 2021; Rhee TG, Kumar M, Ross JS, Coll PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598936>
 15. Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. *J Atheroscler Thromb* 2021; Nakamura M, Ako J, Arai H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33612707>
 16. Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. *Journal of racial and ethnic health disparities* 2021; Mathews L, Han D, Evans MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33594652>
 17. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. *The Journal of thoracic and cardiovascular surgery* 2021; Farsky PS, White J, Al-Khalidi HR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33610365>
 18. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease. *Lipids Health Dis* 2021; 20:12; Mourouzis K, Siasos G, Oikonomou E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583415>
 19. Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: A retrospective observational registry study. *Medicine (Baltimore)* 2021; 100:e24733; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578620>
 20. PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. *Nutrition, metabolism, and cardiovascular diseases : NMCD* 2020; Zeller M, Lambert G, Farnier M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546945>
 21. Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study. *PLoS One* 2021; 16:e0247419; Kim J, Kim HS, Bae YJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630898>
 22. Sex and gender differences in presentation, treatment and outcomes in acute coronary syndrome, a 10 year study from a multi-ethnic Asian population: The Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry. *PLoS One* 2021; 16:e0246474; Lee CY, Liu KT, Lu HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556136>

23. Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture. *PLoS One* 2021; 16:e0247153; Terceño M, Remollo S, Silva Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600491>
24. Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. *Research in social & administrative pharmacy : RSAP* 2021; Seaman KL, Bulsara MK, Sanfilippo FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33558155>
25. [Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management]. *Revue medicale de Liege* 2021; 76:128-133; Lancellotti P, Ancion A, Scheen AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33543860>
26. Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study. *Rheumatology (Oxford)* 2021; Zemedikun DT, Gokhale K, Chandan JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33590842>
27. Commentary: Untangling the Mystery of Statin Therapy in Treating Postoperative Atrial Fibrillation: Does the Underlying Cardiac Pathology Matter? *Seminars in thoracic and cardiovascular surgery* 2021; Pagani FD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600991>
28. Statins After Ischemic Stroke in the Oldest: A Cohort Study Using the Clinical Practice Research Datalink Database. *Stroke* 2021:Strokeaha120030755; Lefeber GJ, Knol W, Souverein PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563018>

Endothelium/inflammation

1. Rosuvastatin Attenuates Rheumatoid Arthritis-Associated Manifestations via Modulation of the Pro- and Anti-inflammatory Cytokine Network: A Combination of In Vitro and In Vivo Studies. *ACS omega* 2021; 6:2074-2084; Qasim S, Alamgeer, Kalsoom S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33521447>
2. Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review. *Frontiers in public health* 2020; 8:600427; Nwadiugwu MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569370>
3. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. *Journal of translational medicine* 2021; 19:62; Zhang

X, Qin Y, Wan X *et*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33568202>

4. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease. *Lipids Health Dis* 2021; 20:12Mourouzis K, Siasos G, Oikonomou E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583415>
5. Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. *Scientific reports* 2021; 11:4126; Hoogeveen RM, Verweij SL, Kaiser Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602971>

Ethnicity

1. Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. *Bmj* 2021; 372:n48; Jia Y, Wen J, Qureshi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33531350>
2. Long-term Prognosis of Mild to Moderate Aortic Stenosis and Coronary Artery Disease. *J Korean Med Sci* 2021; 36:e47; Lee W, Choi W, Kang SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33559407>
3. Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: A retrospective observational registry study. *Medicine (Baltimore)* 2021; 100:e24733; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578620>
4. Sex and gender differences in presentation, treatment and outcomes in acute coronary syndrome, a 10 year study from a multi-ethnic Asian population: The Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry. *PLoS One* 2021; 16:e0246474; Lee CY, Liu KT, Lu HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556136>

FH

1. Late response to rosuvastatin and statin-related myalgia due to SLC01B1, SLC01B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report. *Annals of translational medicine* 2021; 9:76Dagli-Hernandez C, de Freitas RCC, Marçal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553369>
2. Cardiovascular Risk Misperception and Low Awareness of Familial Hypercholesterolemia in Individuals with Severe Hypercholesterolemia. *Arquivos brasileiros de cardiologia* 2021; Santos RD,

Pereira C, Cesena F *et al.*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33566934>

3. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. *Atherosclerosis* 2021; 320:53-60; Vuorio A, Raal F, Kaste M, Kovanen PT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33540179>
4. Pharmacogenomics of statins and familial hypercholesterolemia. *Curr Opin Lipidol* 2021; 32:96-102; Chora JR, Bourbon M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591029>
5. Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. *J Clin Lipidol* 2021; Johansen AK, Bogsrud MP, Roeters van Lennep J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608220>
6. Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? *Thrombosis research* 2021; 200:156-163; Silvino JPP, Carvalho MG, Reis EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33626480>
7. Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents. *Vasc Health Risk Manag* 2021; 17:59-67; Tada H, Takamura M, Kawashiri MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628029>

Genetics

1. Late response to rosuvastatin and statin-related myalgia due to SLC01B1, SLC01B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report. *Annals of translational medicine* 2021; 9:76Dagli-Hernandez C, de Freitas RCC, Marçal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553369>
2. Pharmacogenomics of statins and familial hypercholesterolemia. *Curr Opin Lipidol* 2021; 32:96-102; Chora JR, Bourbon. M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591029>
3. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. *Eur J Prev Cardiol* 2020; Baragetti A, Bonacina F, Da Dalt L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624064>
4. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. *Eur J Prev Cardiol* 2021; Hussain A, Sun C, Selvin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580780>
5. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLC01B1 gene and statin-induced myopathy. *Pharmacogenomics J* 2021; Turongkaravee S, Jittikoon J,

Lukkunaprasit T *et*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608664>

Guidelines

1. Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. *American journal of epidemiology* 2021; Xu Z, Arnold M, Stevens D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33595074>
2. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. *Atherosclerosis. Supplements* 2020; 42:e59-e64; Alings M, Descamps O, Guillon B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589225>
3. Factors predicting statin prescribing for primary prevention: a historical cohort study. *Br J Gen Pract* 2021; 71:e219-e225; Finnikin S, Willis BH, Ryan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33558331>
4. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affairs Healthcare System. *Cardiovasc Drugs Ther* 2021; Jia X, Lee MT, Ramsey DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33523335>
5. Egyptian practical guidance in lipid management 2020. *The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology* 2021; 73:17; Taha H, Badran HM, Kandil H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33620601>
6. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. *Eur J Prev Cardiol* 2020; Blaum C, Seiffert M, Goßling A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580772>
7. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2020; Khan SU, Khan MU, Virani SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624058>
8. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. *Eur J Prev Cardiol* 2021; Koskinas KC, Catapano AL, Baigent C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580792>
9. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. *Eur J Prev Cardiol* 2020; Ray KK, Molemans B, Schoonen WM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580789>

10. Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to Guideline-Based Secondary Stroke Prevention. *J Stroke* 2021; 23:51-60 Pan Y, Li Z, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600702>

LDL- related parameters

1. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. *Atherosclerosis. Supplements* 2020; 42:e49-e58; Landmesser U, Pirillo A, Farnier M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589224>
2. Consistent use of lipid lowering therapy in HIV infection is associated with low mortality. *BMC infectious diseases* 2021; 21:150; Drechsler H, Ayers C, Cutrell J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546621>
3. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affairs Healthcare System. *Cardiovasc Drugs Ther* 2021; Jia X, Lee MT, Ramsey DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33523335>
4. Optimum lipid testing for diabetic patients to enhance clinical care. *Diabetes & metabolic syndrome* 2021; 15:461-464; Devaraj S, Jialal I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33607521>
5. Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real life evidence of Under-treatment from the EPHEBUS registry. *European journal of clinical investigation* 2021:e13528; Mert KU, Başaran Ö, Mert G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630348>
6. Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020? *Eur J Prev Cardiol* 2020; Agha AM, Ballantyne CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624105>
7. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2020; Khan SU, Khan MU, Virani SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624058>
8. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. *Eur J Prev Cardiol* 2021; Koskinas KC, Catapano AL, Baigent C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580792>
9. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. *Eur J Prev*

Cardiol 2020; Ray KK, Molemans B, Schoonen WM *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33580789>

10. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. *Int J Cardiol* 2021; Jojima T, Sakurai S, Wakamatsu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556413>
11. Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. *J Clin Lipidol* 2021; Johansen AK, Bogsrud MP, Roeters van Lennep J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608220>

Lifestyle

1. Cardiovascular-related health behaviors and lifestyle during the COVID-19 pandemic: An infodemiology study. *Am J Prev Cardiol* 2021; 5:100148; Dzaye O, Adelhoefer S, Boakye E, Blaha MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33521755>
2. Statin use moderates the beneficial effects of aerobic exercise on older adults' performances on the Stroop test: A subanalysis. *Experimental gerontology* 2021; 147:111277; Saillant K, Langeard A, Kaushal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600874>
3. Hypolipidemic, anti-inflammatory, and anti-atherosclerotic effects of tea before and after microbial fermentation. *Food science & nutrition* 2021; 9:1160-1170; Deng X, Hou Y, Zhou H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598200>
4. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. *J Am Coll Cardiol* 2021; 77:620-628; Cicero AFG, Fogacci F, Zambon A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33538260>
5. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. *Pharmacological reports : PR* 2021:1-12; Permana H, Huang I, Purwiga A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608850>
6. Comparative effect of physical exercise versus statins on improving arterial stiffness in patients with high cardiometabolic risk: A network meta-analysis. *PLoS Med* 2021; 18:e1003543; Caverro-Redondo I, Deeks JJ, Alvarez-Bueno C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591983>

Meta-analyses

1. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2020; Khan SU, Khan MU, Virani SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624058>
2. Coenzyme Q(10) for Patients With Cardiovascular Disease: JACC Focus Seminar. *J Am Coll Cardiol* 2021; 77:609-619; Raizner AE, Quiñones MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33538259>
3. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. *Journal of clinical gastroenterology* 2021; Wong YJ, Qiu TY, Ng GK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33606427>
4. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLC01B1 gene and statin-induced myopathy. *Pharmacogenomics J* 2021; Turongkaravee S, Jittikoon J, Lukkunaprasit T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608664>
5. Comparative effect of physical exercise versus statins on improving arterial stiffness in patients with high cardiometabolic risk: A network meta-analysis. *PLoS Med* 2021; 18:e1003543; Cavero-Redondo I, Deeks JJ, Alvarez-Bueno C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591983>
6. Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials. *PLoS One* 2021; 16:e0246480; Blais JE, Tong GKY, Pathadka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33561179>
7. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. *Postgraduate medical journal* 2021; Pal R, Banerjee M, Yadav U, Bhattacharjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33541927>
8. [A Meta-analysis on association between statins and colorectal cancer]. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi* 2021; 42:343-350; Qi JH, Wei JN, Zhang ZJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33626626>

Metabolic Syndrome - Diabetes

1. Statins Protect Against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients. *Annals of vascular surgery* 2021; Suh D, Amendola MF, Reeves M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33549796>
2. Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus. *BMJ open*

- diabetes research & care 2021; 9García-Ulloa AC, Lechuga-Fonseca C, Del Razo-Olvera FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33568360>
3. Comparative study of the efficacy of captopril, simvastatin, and L-carnitine as cardioprotective drugs in children with type 1 diabetes mellitus: a randomised controlled trial. *Cardiology in the young* 2021;1-8; Badredeen A, El Razaky O, Erfan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33536102>
 4. Current Trends in the Therapeutic Strategies for Diabetes Management. *Curr Med Chem* 2021; Siva Kumar PM, Prabhawathi V, Zarrabi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602069>
 5. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? *Diabetes Care* 2020; 43:1557-1592; Siegel KR, Ali MK, Zhou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33534729>
 6. Optimum lipid testing for diabetic patients to enhance clinical care. *Diabetes & metabolic syndrome* 2021; 15:461-464; Devaraj S, Jialal I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33607521>
 7. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. *Diabetologia* 2021;1-17; Wargny M, Potier L, Gourdy P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33599800>
 8. Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real life evidence of Under-treatment from the EPHEBUS registry. *European journal of clinical investigation* 2021:e13528; Mert KU, Başaran Ö, Mert G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630348>
 9. Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review. *Frontiers in public health* 2020; 8:600427; Nwadiugwu MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569370>
 10. Physician variation in the de-adoption of ineffective statin and fibrate therapy. *Health services research* 2021; Everhart A, Desai NR, Dowd B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569804>
 11. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. *Int J Cardiol* 2021; Jojima T, Sakurai S, Wakamatsu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556413>
 12. Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat. *Journal of diabetes and metabolic disorders* 2020; 19:1415-1422; Mondol D, Islam MN, Biswas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553033>

13. Lipid metabolism dysregulation in diabetic retinopathy. *Journal of lipid research* 2021; 62:100017; Busik JV.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33581416>
14. Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: A retrospective observational registry study. *Medicine (Baltimore)* 2021; 100:e24733; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578620>
15. Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study. *Rheumatology (Oxford)* 2021; Zemedikun DT, Gokhale K, Chandan JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33590842>

New Treatments

1. Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial. *Adv Ther* 2021; Luan Y, Wang M, Zhao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33638801>
2. Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients. *Current cardiology reports* 2021; 23:19; Macaulay TE, Sheridan E, Ward S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33598864>
3. Inclisiran: First Approval. *Drugs* 2021:1-7; Lamb YN.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33620677>
4. Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. *Drugs in context* 2021; 10; Anderson SL, Bassetti M, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33542739>
5. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. *European heart journal cardiovascular Imaging* 2021; Ota H, Omori H, Kawasaki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33637979>
6. Aortic valvular stenosis - novel therapeutic strategies. *European journal of clinical investigation* 2021:e13527; Natarska J, Kopytek M, Undas A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33621361>
7. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. *Eur J Prev Cardiol* 2020; Blaum C, Seiffert M, Goßling A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580772>
8. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. *Eur J Prev Cardiol* 2020; Gaudet D, López-Sendón JL, Averno M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624041>

9. Novel Experimental Agents for the Treatment of Hypercholesterolemia. *Journal of experimental pharmacology* 2021; 13:91-100; Pećin I, Reiner Ž.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33603500>
10. Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? *Thrombosis research* 2021; 200:156-163; Silvino JPP, Carvalho MG, Reis EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33626480>

Other

1. Core Prescribing Indicators and the Most Commonly Prescribed Medicines in a Tertiary Health Care Setting in a Developing Country. *Adv Pharmacol Pharm Sci* 2021; 2021:6625377; Galappatthy P, Ranasinghe P, Liyanage CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33564747>
2. Antiretroviral Laboratory Monitoring and Implications for HIV Clinical Care in the Era of COVID-19 and Beyond. *AIDS research and human retroviruses* 2021; York L, Fisher JM, Malladi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33567992>
3. Statins and COVID-19: To Suspend or Not to Suspend? That is the Question! *Arquivos brasileiros de cardiologia* 2021; 116:147-152; Ferrari F, Santos RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33566980>
4. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. *Atherosclerosis* 2021; 320:53-60; Vuorio A, Raal F, Kaste M, Kovanen PT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33540179>
5. Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin. *bioRxiv* 2021; Qian Y, Lei T, Patel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33594363>
6. SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets. *BMC Genomics* 2021; 22:125; Li Y, Duche A, Sayer MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602138>
7. Consistent use of lipid lowering therapy in HIV infection is associated with low mortality. *BMC infectious diseases* 2021; 21:150; Drechsler H, Ayers C, Cutrell J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546621>
8. Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. *Bmj* 2021; 372:n48; Jia Y, Wen J, Qureshi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33531350>
9. Implications of a defined daily dose fixed database for drug utilization research studies: The case of statins in Portugal. *Br J Clin Pharmacol* 2021; Abrantes C, Tonin FS, Reis-Pardal J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33576512>

10. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. Clinical drug investigation 2021; Caro L, Prueksaritanont T, Fandozzi CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33527237>
11. Clinically important drug-drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management. Drug Metab Pers Ther 2020; Mahboobipour AA, Baniyasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580642>
12. Case report of a COVID-19-associated myocardial infarction with no obstructive coronary arteries: the mystery of the phantom embolus or local endothelitis. European heart journal. Case reports 2021; 5:ytaa521; Burkert FR, Niederreiter L, Dichtl W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598613>
13. Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. Eur J Prev Cardiol 2020; Nalini M, Shakeri R, Poustchi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624066>
14. Modulation of the Gut Microbiota and Liver Transcriptome by Red Yeast Rice and Monascus Pigment Fermented by Purple Monascus SHM1105 in Rats Fed with a High-Fat Diet. Frontiers in pharmacology 2020; 11:599760; Yang H, Pan R, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33551805>
15. Variation in Cardiologist Statin Prescribing by Clinic Appointment Time. J Am Coll Cardiol 2021; 77:661-662; Oakes AH, Adusumalli S, Snider CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33538261>
16. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. Journal of personalized medicine 2021; 11; Oh TK, Song IA, Jeon YT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578937>
17. Interdependence of Anti-Inflammatory and Antioxidant Properties of Squalene-Implication for Cardiovascular Health. Life (Basel) 2021; 11; Ibrahim N, Naina Mohamed I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33573041>
18. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nature communications 2021; 12:1325; Gupta A, Madhavan MV, Poterucha TJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33637713>
19. Publisher Correction: Genetic interaction networks mediate individual statin drug response in *Saccharomyces cerevisiae*. NPJ systems biology and applications 2020; 6:9; Busby BP, Niktab E, Roberts CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580022>

20. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. *Pharmacological reports* : PR 2021:1-12; Permana H, Huang I, Purwiga A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608850>
21. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. *Postgraduate medical journal* 2021; Pal R, Banerjee M, Yadav U, Bhattacharjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33541927>
22. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. *Transl Med Commun* 2021; 6:3; Peymani P, Dehesh T, Aligolighasemabadi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33521322>

PAD and statins

1. Racial and Gender Disparity in Achieving Optimal Medical Therapy for Inpatients with Peripheral Artery Disease. *Ann Vasc Med Res* 2020; 7; Gober L, Bui A, Ruddy JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33585679>
2. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. *Diabetologia* 2021:1-17; Wargny M, Potier L, Gourdy P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33599800>

Pleiotropic effects of statins

1. Rosuvastatin Attenuates Rheumatoid Arthritis-Associated Manifestations via Modulation of the Pro- and Anti-inflammatory Cytokine Network: A Combination of In Vitro and In Vivo Studies. *ACS omega* 2021; 6:2074-2084; Qasim S, Alamgeer, Kalsoom S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33521447>
2. Statins Protect Against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients. *Annals of vascular surgery* 2021; Suh D, Amendola MF, Reeves M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33549796>
3. Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. *Anticancer Drugs* 2021; Asari K, Sun WT, Kok ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33587350>
4. Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines. *Asian Pacific journal of cancer prevention* : APJCP 2021; 22:33-

- 42; Rezano A, Ridhayanti F, Rangkuti AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33576210>
5. Effect of Statins on Platelet Activation and Function: From Molecular Pathways to Clinical Effects. *BioMed research international* 2021; 2021:6661847; Nenna A, Nappi F, Lusini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33564680>
 6. Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin. *bioRxiv* 2021; Qian Y, Lei T, Patel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33594363>
 7. Simvastatin attenuates spatial memory impairment via inhibiting microgliosis and apoptotic cell death against ethanol induced neurotoxicity in the developing rat hippocampus. *Brain Res* 2021:147341; Jafari M, Hojati V, Khaksari M, Vaezi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33548270>
 8. Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study. *Can Assoc Radiol J* 2021:846537120988262; Avery A, Sussman M, Longo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563030>
 9. Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching. *Cancer research* 2021; Yu R, Longo J, van Leeuwen JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602786>
 10. Emerging views of statin pleiotropy and cholesterol lowering. *Cardiovascular research* 2021; Yu D, Liao JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33533892>
 11. Targeting cholesterol metabolism as efficient antiviral strategy against the Hepatitis E virus. *Cell Mol Gastroenterol Hepatol* 2021; Glitscher M, Martín DH, Woytinek K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33601063>
 12. Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training. *Drugs Aging* 2021; Alturki M, Liberman K, Delaere A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33543410>
 13. Statin use is associated with reduced mortality after respiratory viral infection. *ERJ Open Res* 2021; Franco-Peláez JA, Esteban-Lucia L, Zambrano Chacón M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569498>
 14. Reduced ¹⁸F-sodium fluoride activity in coronary plaques after statin therapy. *European heart journal cardiovascular Imaging* 2021; Dietz M, Chironi G, Faraggi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33537762>

15. Can Simvastatin reduce COPD Exacerbations? A Randomised Double Blind Controlled Study. *The European respiratory journal* 2021; Schenk P, Spiel AO, Hüttinger F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33574076>
16. Inhibition of the mevalonate pathway improves myocardial fibrosis. *Experimental and therapeutic medicine* 2021; 21:224; Xu H, Shen Y, Liang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33603833>
17. Atorvastatin Attenuates Isoflurane-Induced Activation of ROS-p38MAPK/ATF2 Pathway, Neuronal Degeneration, and Cognitive Impairment of the Aged Mice. *Frontiers in aging neuroscience* 2020; 12:620946; Liu P, Gao Q, Guan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33519423>
18. Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves' Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways. *Frontiers in endocrinology* 2020; 11:607968; Wei YH, Liao SL, Wang SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33597925>
19. Use of Simvastatin, Fibrin Clots, and Their Combination to Improve Human Ovarian Tissue Grafting for Fertility Restoration After Anti-Cancer Therapy. *Frontiers in oncology* 2020; 10:598026; Magen R, Shufaro Y, Daykan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33552971>
20. Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates. *Frontiers in pharmacology* 2020; 11:642171; Badr-Eldin SM, Alhakamy NA, Fahmy UA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33633571>
21. Modulation of the Gut Microbiota and Liver Transcriptome by Red Yeast Rice and Monascus Pigment Fermented by Purple Monascus SHM1105 in Rats Fed with a High-Fat Diet. *Frontiers in pharmacology* 2020; 11:599760; Yang H, Pan R, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33551805>
22. Simvastatin in vitiligo: an update with recent review of the literature. *International journal of dermatology* 2021; Hasan R, Agarwal K, Podder I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33554328>
23. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves' disease. *J Clin Endocrinol Metab* 2021; Nilsson A, Tsoumani K, Planck T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33560351>
24. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. *Journal of clinical gastroenterology* 2021; Hajifathalian K, Tafesh Z, Rosenblatt R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33606428>

25. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. *Journal of clinical gastroenterology* 2021; Wong YJ, Qiu TY, Ng GK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33606427>
26. Lipid metabolism dysregulation in diabetic retinopathy. *Journal of lipid research* 2021; 62:100017; Busik JV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33581416>
27. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. *Journal of the National Cancer Institute* 2021; Bhat K, Saki M, Cheng F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556960>
28. Can Combination of Simvastatin and Melatonin Create a Synergistic Effect on Bone Regeneration? *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons* 2021; Koç O, Tüz HH, Ocak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33524327>
29. The effect of topical administration of simvastatin on entochondroostosis and intramembranous ossification: An animal experiment. *J Orthop Translat* 2021; 28:1-9; Dang L, Zhu J, Song C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33575165>
30. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. *Journal of personalized medicine* 2021; 11; Oh TK, Song IA, Jeon YT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578937>
31. Effects of Simvastatin on Tissue Factor Pathway of Blood Coagulation in STATCOPE (Simvastatin in the Prevention of COPD Exacerbations) Trial. *Journal of thrombosis and haemostasis : JTH* 2021; Rao AK, Del Carpio-Cano F, Janapati S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33638931>
32. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. *Journal of translational medicine* 2021; 19:62; Zhang X, Qin Y, Wan X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33568202>
33. Angiogenic Effect of Pravastatin Alone and with Sera from Healthy and Complicated Pregnancies Studied by in vitro Vasculogenesis/Angiogenesis Assay. *Journal of vascular research* 2021:1-9; Virtanen A, Huttala O, Tihtonen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33571991>
34. Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. *JAMA network open* 2021; 4:e2036315; Scott FI, Vajravelu RK, Mamtani R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33533930>

35. Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation? Kaohsiung J Med Sci 2021; Zhelyazkova-Savova MD, Yotov YT, Nikolova MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634559>
36. Effects of atorvastatin and resveratrol against the experimental endometriosis; evidence for glucose and monocarboxylate transporters, neoangiogenesis. Life sciences 2021; 272:119230; Bahrami A, Ayen E, Razi M, Behfar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600864>
37. Comparison of the Effects of Statins on A549 Non-small-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out. Lipids 2021; Aksoy HN, Ceylan C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611813>
38. Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves' Ophthalmopathy through the Regulation of FoxO3a Signaling. Mediators Inflamm 2021; 2021:8888913; Wei YH, Liao SL, Wang CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33542676>
39. [Statin use in patients with liver disease - overview and results from a retrospective observational study]. MMW Fortschritte der Medizin 2021; 163:74-77; Markova A, Wedemeyer H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591527>
40. Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases. Molecular and cellular biochemistry 2021; Beales ILP, Ogunwobi OO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33582946>
41. A Multi-Objective Approach for Drug Repurposing in Preeclampsia. Molecules (Basel, Switzerland) 2021; 26; Tejera E, Pérez-Castillo Y, Chamorro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546161>
42. Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats. Naunyn-Schmiedeberg's archives of pharmacology 2021; Alshogran OY, Nusair SD, El-Elimat T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630121>
43. Candidate drugs for preventive treatment of unruptured intracranial aneurysms: A cross-sectional study. PLoS One 2021; 16:e0246865; Shimizu K, Imamura H, Tani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33577580>
44. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgraduate medical journal 2021; Pal R, Banerjee M, Yadav U, Bhattacharjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33541927>

45. Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. *Ren Fail* 2021; 43:302-306; Zou P, Li H, Cai J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583321>
46. Simvastatin suppresses renal cell carcinoma cells by regulating DDX5/DUSP5. *Scandinavian journal of urology* 2021:1-7; Qiu Y, Zhao Y, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517812>
47. Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial. *Schizophr Bull* 2021; Sommer IE, Gangadin SS, de Witte LD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608711>
48. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. *Translational lung cancer research* 2021; 10:128-142; Luo Y, Yang Y, Peng P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569299>
49. [A Meta-analysis on association between statins and colorectal cancer]. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi* 2021; 42:343-350; Qi JH, Wei JN, Zhang ZJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33626626>

Registry data

1. Comparison of Patients With Nonobstructive Coronary Artery Disease With Versus Without Myocardial Infarction (From the VA Clinical Assessment Reporting and Tracking [CART] Program). *Am J Cardiol* 2021; Kovach CP, Hebbe A, O'Donnell CI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33539858>
2. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. *Atherosclerosis. Supplements* 2020; 42:e49-e58; Landmesser U, Pirillo A, Farnier M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589224>
3. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affairs Healthcare System. *Cardiovasc Drugs Ther* 2021; Jia X, Lee MT, Ramsey DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33523335>
4. Statin use is associated with reduced mortality after respiratory viral infection. *ERJ Open Res* 2021; 7; Franco-Peláez JA, Esteban-Lucia L, Zambrano Chacón M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569498>
5. Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real life evidence of Under-treatment from the

- EPHESUS registry. European journal of clinical investigation 2021:e13528; Mert KU, Başaran Ö, Mert G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630348>
6. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol 2021; Hussain A, Sun C, Selvin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580780>
 7. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. Eur J Prev Cardiol 2021; Koskinas KC, Catapano AL, Baigent C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580792>
 8. Cardiovascular event rates increase after each recurrence and associate with poor statin adherence. Eur J Prev Cardiol 2020; Lassenius MI, Toppila I, Bergius S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33611439>
 9. Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. Eur J Prev Cardiol 2020; Nalini M, Shakeri R, Poustchi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624066>
 10. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2020; Ray KK, Molemans B, Schoonen WM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580789>
 11. Statin treatment reduces the risk of death among elderly frail patients: evidence from a large population-based cohort. Eur J Prev Cardiol 2020; Rea F, Mancina G, Corrao G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624076>
 12. Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US. Frontiers in medicine 2021; 8:639804; Marić I, Oskotsky T, Kostić I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33614688>
 13. Physician variation in the de-adoption of ineffective statin and fibrate therapy. Health services research 2021; Everhart A, Desai NR, Dowd B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569804>
 14. Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018. J Am Geriatr Soc 2021; Rhee TG, Kumar M, Ross JS, Coll PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598936>
 15. Common Medications and Intracerebral Hemorrhage: The ARIC Study. J Am Heart Assoc 2021; 10:e014270; Sharma R, Matsushita K, Wu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33586464>
 16. Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. J Atheroscler Thromb 2021;

Nakamura M, Ako J, Arai H *et al.*

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33612707>

17. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves' disease. *J Clin Endocrinol Metab* 2021; Nilsson A, Tsoumani K, Planck T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33560351>
18. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. *Journal of clinical gastroenterology* 2021; Hajifathalian K, Tafesh Z, Rosenblatt R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33606428>
19. Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. *J Clin Lipidol* 2021; Johansen AK, Bogsrud MP, Roeters van Lennep J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608220>
20. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. *Journal of personalized medicine* 2021; 11; Oh TK, Song IA, Jeon YT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578937>
21. Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. *Journal of racial and ethnic health disparities* 2021; Mathews L, Han D, Evans MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33594652>
22. Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. *JAMA network open* 2021; 4:e2036315; Scott FI, Vajravelu RK, Mamtani R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33533930>
23. Geographic Variation of Statin Use Among US Nursing Home Residents With Life-limiting Illness. *Medical care* 2021; Mack DS, Baek J, Tjia J, Lapane KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33560713>
24. Effect of statin treatment in patients with acute myocardial infarction with prediabetes and type 2 diabetes mellitus: A retrospective observational registry study. *Medicine (Baltimore)* 2021; 100:e24733; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33578620>
25. [Statin use in patients with liver disease - overview and results from a retrospective observational study]. *MMW Fortschritte der Medizin* 2021; 163:74-77; Markova A, Wedemeyer H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591527>
26. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. *Nature communications* 2021; 12:1325Gupta A, Madhavan MV, Poterucha TJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33637713>

27. PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. Nutrition, metabolism, and cardiovascular diseases : NMCD 2020; Zeller M, Lambert G, Farnier M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546945>
28. Statins and risk of diverticular disease: Nested case-control study. Pharmacoepidemiol Drug Saf 2021; Skajaa N, Schønfeldt Troelsen F, Pedersen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583126>
29. Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study. PLoS One 2021; 16:e0247419; Kim J, Kim HS, Bae YJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630898>
30. Candidate drugs for preventive treatment of unruptured intracranial aneurysms: A cross-sectional study. PLoS One 2021; 16:e0246865; Shimizu K, Imamura H, Tani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33577580>
31. Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture. PLoS One 2021; 16:e0247153; Terceño M, Remollo S, Silva Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600491>
32. Statins After Ischemic Stroke in the Oldest: A Cohort Study Using the Clinical Practice Research Datalink Database. Stroke 2021:Strokeaha120030755; Lefeber GJ, Knol W, Souverein PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563018>
33. Venous thromboembolism and risk of cancer in users of statins: A Danish population-based cohort study. Thrombosis research 2021; 201:1-5; Skajaa N, Nagy D, Schønfeldt Troelsen F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33621859>
34. Statins as a Medical Adjunct in the Surgical Management of Chronic Subdural Hematomas. World neurosurgery 2021; Guidry BS, Kelly KA, Yengo-Kahn AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33610873>

Renal Disease

1. An Environmental Scan of Ambulatory Care Quality Indicators for Patients With Advanced Kidney Disease Currently Used in Canada. Canadian journal of kidney health and disease 2021; 8:2054358121991096; Hingwala J, Molnar AO, Mysore P, Silver SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33614057>
2. Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease. High blood pressure & cardiovascular prevention : the official journal of the Italian

- Society of Hypertension 2021; D'Angelo K, Paul S, Ranjeeta F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33625694>
3. Controversies: Stroke Prevention in Chronic Kidney Disease. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2021;105679; Lau WL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33640261>
 4. Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats. Naunyn-Schmiedeberg's archives of pharmacology 2021; Alshogran OY, Nusair SD, El-Elimat T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33630121>
 5. Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. Ren Fail 2021; 43:302-306; Zou P, Li H, Cai J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583321>
 6. Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. Scientific reports 2021; 11:4126; Hoogeveen RM, Verweij SL, Kaiser Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33602971>

Reviews

1. Effect of Statins on Platelet Activation and Function: From Molecular Pathways to Clinical Effects. BioMed research international 2021; 2021:6661847; Nenna A, Nappi F, Lusini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33564680>
2. Emerging views of statin pleiotropy and cholesterol lowering. Cardiovascular research 2021; Yu D, Liao JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33533892>
3. Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients. Current cardiology reports 2021; 23:19; Macaulay TE, Sheridan E, Ward S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598864>
4. Inclisiran: First Approval. Drugs 2021:1-7; Lamb YN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33620677>
5. Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. Drugs in context 2021; 10; Anderson SL, Bassetti M, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33542739>
6. Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review. Frontiers in public health 2020; 8:600427; Nwadiugwu MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33569370>

7. Simvastatin in vitiligo: an update with recent review of the literature. *International journal of dermatology* 2021; Hasan R, Agarwal K, Podder I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33554328>
8. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. *J Am Coll Cardiol* 2021; 77:620-628; Cicero AFG, Fogacci F, Zambon A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33538260>
9. Lipid metabolism dysregulation in diabetic retinopathy. *Journal of lipid research* 2021; 62:100017; Busik JV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33581416>
10. Statin-Associated Myalgias and Muscle Injury-Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein. *The Medical clinics of North America* 2021; 105:263-272; Mammen AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589101>
11. Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents. *Vasc Health Risk Manag* 2021; 17:59-67; Tada H, Takamura M, Kawashiri MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628029>

Safety and side effects

1. Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report. *Annals of translational medicine* 2021; 9:76; Dagli-Hernandez C, de Freitas RCC, Marçal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33553369>
2. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. *BMC pharmacology & toxicology* 2021; 22:11; Choi JY, Choi CU, Choi BG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33541430>
3. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. *Bmj* 2021; 372:n135; Herrett E, Williamson E, Brack K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33627334>
4. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. *Clinical drug investigation* 2021; Caro L, Prueksaritanont T, Fandozzi CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33527237>
5. The effect of atorvastatin on recurrence of chronic subdural hematoma after novel YL-1 puncture needle surgery. *Clin Neurol Neurosurg* 2021; 202:106548; Wang D, Wang H, Xu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33609954>

6. Atorvastatin-Induced Refractory Thrombocytopenia. *Cureus* 2021; 13:e12502; Ghuman J, Manasewitsch NT, Ghuman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33564510>
7. Clinically important drug-drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management. *Drug Metab Pers Ther* 2020; Mahboobipour AA, Baniyasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580642>
8. The SAMSON trial: Using a Placebo to Improve Medication Tolerability. *European heart journal. Cardiovascular pharmacotherapy* 2021; Nelson AJ, Pagidipati NJ, Granger CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33638980>
9. Statin-induced autoimmune myopathy: a case report. *Eur J Hosp Pharm* 2021; 28:115-117; Alzueta N, Marin M, Castresana M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608442>
10. Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020? *Eur J Prev Cardiol* 2020; Agha AM, Ballantyne CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624105>
11. Statin use moderates the beneficial effects of aerobic exercise on older adults' performances on the Stroop test: A subanalysis. *Experimental gerontology* 2021; 147:111277; Saillant K, Langeard A, Kaushal N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600874>
12. The ameliorative effect of atorvastatin on serum testosterone and testicular oxidant/antioxidant system of HFD-fed male albino rats. *F1000Research* 2020; 9:1300; Esmail M, Kandeil M, El-Zanaty AM, Abdel-Gabbar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628436>
13. Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. *Frontiers in pharmacology* 2020; 11:600255; Pedraza L, Laosa O, Rodríguez-Mañas L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33613279>
14. Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease. *High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension* 2021; D'Angelo K, Paul S, Ranjeeta F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33625694>
15. Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver. *Internal and emergency medicine* 2021; Gitto S, Campani C, Generini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33550534>

16. Coenzyme Q(10) for Patients With Cardiovascular Disease: JACC Focus Seminar. *J Am Coll Cardiol* 2021; 77:609-619; Raizner AE, Quiñones MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33538259>
17. Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation? *Kaohsiung J Med Sci* 2021; Zhelyazkova-Savova MD, Yotov YT, Nikolova MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634559>
18. Statin-Associated Myalgias and Muscle Injury-Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein. *The Medical clinics of North America* 2021; 105:263-272; Mammen AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33589101>
19. [Statin use in patients with liver disease - overview and results from a retrospective observational study]. *MMW Fortschritte der Medizin* 2021; 163:74-77Markova A, Wedemeyer H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33591527>
20. Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice. *Mol Brain* 2021; 14:41Guo Y, Zou G, Qi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33627175>
21. Statins and risk of diverticular disease: Nested case-control study. *Pharmacoepidemiol Drug Saf* 2021; Skajaa N, Schønfeldt Troelsen F, Pedersen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583126>
22. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. *Pharmacogenomics J* 2021; Turongkaravee S, Jittikoon J, Lukkunaprasit T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608664>
23. Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials. *PLoS One* 2021; 16:e0246480; Blais JE, Tong GKY, Pathadka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33561179>
24. Statin use is associated with reduced motor recovery after spinal cord injury. *Spinal Cord Ser Cases* 2021; 7:8; Triplet EM, Scarisbrick IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33536407>
25. Impact of Statins on Hematoma, Edema, Seizures, Vascular Events, and Functional Recovery After Intracerebral Hemorrhage. *Stroke* 2021:Strokeaha120029345; Sprügel MI, Kuramatsu JB, Volbers B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517701>
26. Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4. *Toxicology letters* 2021; 342:85-94; Zheng N, Wei A, Wu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600922>

Stroke and CNS

1. Effect of High-Density Lipoprotein Cholesterol Levels on Overall Survival and Major Adverse Cardiovascular and Cerebrovascular Events. *Am J Cardiol* 2021; Kaur M, Ahuja KR, Khubber S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33535058>
2. Impact of statin pretreatment on the complications of carotid stenting in asymptomatic patients: observational study. *BMC Neurol* 2021; 21:75; Jang SH, Kwon DH, Han MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33588788>
3. Simvastatin attenuates spatial memory impairment via inhibiting microglialosis and apoptotic cell death against ethanol induced neurotoxicity in the developing rat hippocampus. *Brain Res* 2021:147341; Jafari M, Hojati V, Khaksari M, Vaezi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33548270>
4. The effect of atorvastatin on recurrence of chronic subdural hematoma after novel YL-1 puncture needle surgery. *Clin Neurol Neurosurg* 2021; 202:106548; Wang D, Wang H, Xu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33609954>
5. Common Medications and Intracerebral Hemorrhage: The ARIC Study. *J Am Heart Assoc* 2021; 10:e014270; Sharma R, Matsushita K, Wu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33586464>
6. Case report: 68 yo Chinese-American woman with high HDL-C and ischemic stroke attributed to intracranial atherosclerotic stenosis. *J Clin Lipidol* 2021; Gong J, Asher SB, Cucchiara B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33573892>
7. Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial. *Journal of neurology* 2021; Yang WY, Li YF, Wang ZR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33555418>
8. Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to Guideline-Based Secondary Stroke Prevention. *J Stroke* 2021; 23:51-60; Pan Y, Li Z, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600702>
9. Controversies: Stroke Prevention in Chronic Kidney Disease. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* 2021:105679; Lau WL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33640261>
10. Candidate drugs for preventive treatment of unruptured intracranial aneurysms: A cross-sectional study. *PLoS One* 2021; 16:e0246865; Shimizu K, Imamura H, Tani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33577580>

11. Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture. *PLoS One* 2021; 16:e0247153; Terceño M, Remollo S, Silva Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600491>
12. Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. *Research in social & administrative pharmacy : RSAP* 2021; Seaman KL, Bulsara MK, Sanfilippo FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33558155>
13. Statin use is associated with reduced motor recovery after spinal cord injury. *Spinal Cord Ser Cases* 2021; 7:8; Triplet EM, Scarisbrick IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33536407>
14. Statins After Ischemic Stroke in the Oldest: A Cohort Study Using the Clinical Practice Research Datalink Database. *Stroke* 2021:Strokeaha120030755; Lefeber GJ, Knol W, Souverein PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563018>
15. Impact of Statins on Hematoma, Edema, Seizures, Vascular Events, and Functional Recovery After Intracerebral Hemorrhage. *Stroke* 2021:Strokeaha120029345; Sprügel MI, Kuramatsu JB, Volbers B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517701>
16. Treatment and Predictors of Recurrent Internal Carotid Artery In-Stent Restenosis. *Vascular and endovascular surgery* 2021:1538574421993716; Mihály Z, Vértes M, Entz L, Dósa E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563130>
17. Statins as a Medical Adjunct in the Surgical Management of Chronic Subdural Hematomas. *World neurosurgery* 2021; Guidry BS, Kelly KA, Yengo-Kahn AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33610873>

Triglycerides/HDL

1. Effect of High-Density Lipoprotein Cholesterol Levels on Overall Survival and Major Adverse Cardiovascular and Cerebrovascular Events. *Am J Cardiol* 2021; Kaur M, Ahuja KR, Khubber S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33535058>
2. Triglycerides and risk of atherosclerotic cardiovascular disease: An update. *Arch Cardiovasc Dis* 2021; Farnier M, Zeller M, Masson D, Cottin Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546998>
3. Optimum lipid testing for diabetic patients to enhance clinical care. *Diabetes & metabolic syndrome* 2021; 15:461-464; Devaraj S, Jialal I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33607521>
4. Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020? *Eur J Prev*

Cardiol 2020; Agha AM, Ballantyne CM.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33624105>

5. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. *Eur J Prev Cardiol* 2021; Hussain A, Sun C, Selvin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33580780>
6. Case Report: Hypertriglyceridemia and Premature Atherosclerosis in a Patient With Apolipoprotein E Gene $\epsilon 2\epsilon 1$ Genotype. *Frontiers in cardiovascular medicine* 2020; 7:585779; Limonova AS, Ershova AI, Meshkov AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33537346>
7. Case report: 68 yo Chinese-American woman with high HDL-C and ischemic stroke attributed to intracranial atherosclerotic stenosis. *J Clin Lipidol* 2021; Gong J, Asher SB, Cucchiara B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33573892>

Trials

1. Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial. *Adv Ther* 2021; Luan Y, Wang M, Zhao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33638801>
2. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. *Bmj* 2021; 372:n135; Herrett E, Williamson E, Brack K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33627334>
3. Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. *Bmj* 2021; 372:n48; Jia Y, Wen J, Qureshi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33531350>
4. ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin-angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry. *Cardiology journal* 2021; Kim YH, Her AY, Jeong MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33634844>
5. The effect of atorvastatin on recurrence of chronic subdural hematoma after novel YL-1 puncture needle surgery. *Clin Neurol Neurosurg* 2021; 202:106548; Wang D, Wang H, Xu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33609954>
6. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. *Diabetologia* 2021:1-17; Wargny M, Potier L, Gourdy P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33599800>

7. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. Drug design, development and therapy 2021; 15:651-658; Yang E, Yoo H, Jang IJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33628012>
8. The SAMSON trial: Using a Placebo to Improve Medication Tolerability. European heart journal. Cardiovascular pharmacotherapy 2021; Nelson AJ, Pagidipati NJ, Granger CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33638980>
9. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2021:1-8; Akbar MIA, Yosediputra A, Pratama RE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33522342>
10. Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial. Journal of neurology 2021; Yang WY, Li YF, Wang ZR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33555418>
11. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. The Journal of thoracic and cardiovascular surgery 2021; Farsky PS, White J, Al-Khalidi HR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33610365>
12. Effects of Simvastatin on Tissue Factor Pathway of Blood Coagulation in STATCOPE (Simvastatin in the Prevention of COPD Exacerbations) Trial. Journal of thrombosis and haemostasis : JTH 2021; Rao AK, Del Carpio-Cano F, Janapati S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33638931>
13. Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. Ren Fail 2021; 43:302-306; Zou P, Li H, Cai J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33583321>
14. Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial. Schizophr Bull 2021; Sommer IE, Gangadin SS, de Witte LD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33608711>

Women and elderly

1. Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training. Drugs

- Aging 2021; Alturki M, Liberman K, Delaere A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33543410>
2. Statin treatment reduces the risk of death among elderly frail patients: evidence from a large population-based cohort. *Eur J Prev Cardiol* 2020; Rea F, Mancina G, Corrao G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33624076>
 3. Use of Simvastatin, Fibrin Clots, and Their Combination to Improve Human Ovarian Tissue Grafting for Fertility Restoration After Anti-Cancer Therapy. *Frontiers in oncology* 2020; 10:598026; Magen R, Shufaro Y, Daykan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33552971>
 4. Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018. *J Am Geriatr Soc* 2021; Rhee TG, Kumar M, Ross JS, Coll PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33598936>
 5. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2021:1-8; Akbar MIA, Yosediputra A, Pratama RE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33522342>
 6. Angiogenic Effect of Pravastatin Alone and with Sera from Healthy and Complicated Pregnancies Studied by in vitro Vasculogenesis/Angiogenesis Assay. *Journal of vascular research* 2021:1-9; Virtanen A, Huttala O, Tihtonen K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33571991>
 7. Effects of atorvastatin and resveratrol against the experimental endometriosis; evidence for glucose and monocarboxylate transporters, neoangiogenesis. *Life sciences* 2021; 272:119230; Bahrami A, Ayen E, Razi M, Behfar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33600864>
 8. Geographic Variation of Statin Use Among US Nursing Home Residents With Life-limiting Illness. *Medical care* 2021; Mack DS, Baek J, Tjia J, Lapane KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33560713>
 9. A Multi-Objective Approach for Drug Repurposing in Preeclampsia. *Molecules (Basel, Switzerland)* 2021; 26; Tejera E, Pérez-Castillo Y, Chamorro A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33546161>
 10. Sex and gender differences in presentation, treatment and outcomes in acute coronary syndrome, a 10 year study from a multi-ethnic Asian population: The Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry. *PLoS One* 2021; 16:e0246474; Lee CY, Liu KT, Lu HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33556136>

11. Statins After Ischemic Stroke in the Oldest: A Cohort Study Using the Clinical Practice Research Datalink Database. Stroke 2021:Strokeaha120030755; Lefeber GJ, Knol W, Souverein PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33563018>

This activity is supported by an educational grant from Viatrix.
© P.J. Lansberg